Advances on disease modifying drugs for post⁃stroke epilepsy

Abstract

Post⁃stroke epilepsy (PSE) patients generally respond well to low⁃dose antiepileptic seizure medicine (ASM), but some patients still develop drug⁃resistant epilepsy (DRE). Thus, the development of effective drugs that can prevent or reverse epilepsy and disease modifying therapy (DMT) drugs are urgently needed. It was proved that new ASM such as levetiracetam (LVT), lamotrigine (LTG) and zonisamide, natural compounds such as cannabidiol and polyphenolic compounds, mitochondrial antioxidants and non⁃steroidal anti⁃inflammatory drug (NSAID) can not only control seizure but also intervene the occurrence of PSE, playing anti⁃epileptogenic and DMT role. This article intends to further summarize DMT drugs for PSE, providing new research ideas for PSE modifying therapy.

Keywords

• epilepsy
• stroke
• anticonvulsants
• disease modifying therapy (not in mesh)
• neuroprotection
• review